<DOC>
	<DOC>NCT00915187</DOC>
	<brief_summary>To examine the safety and immunogenicity of two formulation of liposomal adjuvant / delivery system (VaxiSomeTM=CCS-Cholesterol [CCS/C]), combined with commercial influenza vaccine in an elderly healthy population when given once intramuscularly (IM).</brief_summary>
	<brief_title>Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>65 years of age or older, mentally competent, willing and able to give written informed consent prior to study entry, male or female; able to comply with all the study requirements; in stable good health as determined by medical history; physical examination; clinical judgment of the investigator. Have adequate renal function (renal clearance of at &gt; 30ml/min) Have normal liver function (hepatic transaminases [ALT and AST] &lt; 43 U/L) Have hemoglobin &gt; 11.5 g/L Any serious chronic or acute disease (in the judgment of the investigator) including but not limited to: cancer, except for localized skin cancer; Advanced congestive heart failure; Acute exacerbation of Chronic obstructive pulmonary disease (COPD); Autoimmune disease, Acute or progressive hepatic disease; Acute or progressive renal disease with a renal clearance of at &lt; 30ml/min ; Severe neurological or psychiatric disorder; History of Guillain Barr√© syndrome; Severe asthma. Clinically significant symptoms of neurological disease; untreated hypertension; increased liver enzymes. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Vaccination, influenza prevention</keyword>
</DOC>